Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
Liver Cancer
.
2023 Jan 16;12(2):184-187.
doi: 10.1159/000529139.
eCollection 2023 Jun.
Authors
Heewon Bae
1
,
Je Ryung Gil
2
,
Moon Hyung Lee
3
,
Taekyu Lim
4
Affiliations
1
Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Republic of Korea.
2
Division of Radiology, Veterans Health Service Medical Center, Seoul, Republic of Korea.
3
Division of Gastroenterology, Veterans Health Service Medical Center, Seoul, Republic of Korea.
4
Division of Hematology-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea.
PMID:
37325494
PMCID:
PMC10267512
DOI:
10.1159/000529139
No abstract available
Grants and funding
The authors did not receive any research funding.